Lavybens Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -26.93%
- Profit Growth -20.36%
- Ebitda -11.32%
- Net Worth 6.99%
- Total Assets 15.24%
About Lavybens Pharmaceuticals
Lavybens Pharmaceuticals Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 December 2012 and has a history of 12 years and two months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Himabindu Yella, Srinivasu Vallem, and Venkata Pechetti serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TG2012PTC084558
- Company No.
084558
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Lavybens Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Himabindu Yella  | Director | 03-Dec-2012 | Current |
| Srinivasu Vallem | Director | 03-Dec-2012 | Current |
| Venkata Pechetti | Director | 03-Dec-2012 | Current |
Financial Performance of Lavybens Pharmaceuticals.
Lavybens Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 26.93% decrease. The company also saw a substantial fall in profitability, with a 20.36% decrease in profit. The company's net worth moved up by a moderate rise of 6.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lavybens Pharmaceuticals?
In 2020, Lavybens Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lavybens Pharmaceuticals?
Unlock and access historical data on people associated with Lavybens Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lavybens Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lavybens Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.